VIRX: Viracta Narx/daromad koeffitsiyenti
Viracta Therapeutics kuchli patent himoyasi bilan ta'minlangan global kengayishga ega bo'lgan ilg'or onkologik dori vositalarini ishlab chiqadi. Brend virus genlarini faollashtirish orqali limfomalarga qarshi kurashishning aniq usuli bilan qadrlanadi. Hozirda kompaniya "kick and kill" printsipiga asoslangan Epstein-Barr virusiga qarshi agentlar liniyasini ishlab chiqmoqda. P/S koeffitsiyentining tebranishlari bozor bahosini aniq namoyish etadi, ko'rsatkichi esa joriy dinamikani aks ettiradi.
Viracta Therapeutics (VIRX) - koʻrsatkichlar kesimi va moliyaviy hisobotlar
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- bozor kapitallashuvi haqida ma'lumot:
- kompaniyaning balans qiymati tafsilotlari:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning xususiy kapitalga nisbati Viracta Therapeutics|VIRX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli kreditlarning kapitalga nisbati viracta.com|VIRX - Kompaniyaning jamlangan qarzlari|Balans kapitallashuviga qarzlar Viracta|VIRX - Kompaniyaning uzoq muddatli majburiyatlari|Kompaniyaning qisqa muddatli kredit va qarzlari Viracta Therapeutics|Oraliq likvidlik koeffitsiyenti viracta.com
- foyda va qiymat multiplikatorlari haqida ma'lumot:
VIRX - Sof foyda|Kutilayotgan sof daromad Viracta Therapeutics|VIRX - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati viracta.com|VIRX - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Viracta|VIRX - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) Viracta Therapeutics|VIRX - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik dinamikasi viracta.com|VIRX - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi Viracta Therapeutics
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning umumiy tahlili:VIRX Viracta Therapeutics Inc.
P/S koeffitsiyenti biznesning bozor qiymatini uning yillik savdo hajmi bilan solishtiradi, bu esa daromadning har bir birligi uchun to'langan premiumni aniqlash imkonini beradi. Viracta Therapeutics (VIRX) kompaniyasining narx/savdo koeffitsiyentini tahlil qilish aktivlar qadrsizlangan paytlarda kirish nuqtalarini aniqlashga yordam beradi, chunki kompaniyaning kapitalizatsiyasi saratoni virusli shakllarini davolashda maqsadli genlarni boshqarish uchun inqilobiy epigenetik dori vositalarini ishlab chiqishga asoslangan.
Viracta Therapeutics kimlar bilan raqobatlashadi
Narxning daromadga nisbati ONC (beigene.com)|P/S multiplikatori HALO (Halozyme)|Narx/daromad koeffitsiyenti Revolution Medicines Inc (RVMD)|AAPG - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati CGON (CG Oncology Therapeutics)|URGN: P/S multiplikatori|bicara.com (BCAX) - P/S multiplikatori|PSNL (Personalis) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Erasca Inc (ERAS)|Kapitalizatsiyaning daromadga nisbati DCTH (Delcath)|Kapitalizatsiyaning sotish hajmiga nisbati YMAB|P/S multiplikatori AURA (Aura Biosciences, Inc.)|P/S multiplikatori Candel Therapeutics Inc. CADL|ARAY: Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics, Inc) - Kapitalizatsiyaning daromadga nisbati|CTOR: Kapitalizatsiyaning sotish hajmiga nisbati|HURA (TuHURA Biosciences Inc.) - P/S multiplikatori|TARA: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori FATE|WHWK - Sotuvga nisbatan narx|Narxning daromadga nisbati TScan Therapeutics, Inc. TCRX|Bozor kapitallashuvining daromadga nisbati CSBR|XBiotech USA - P/S multiplikatori|CVM - P/S multiplikatori|OS Therapies (OSTX) - Narxning daromadga nisbati|Narxning sotuvga nisbati RADX (radiopharmtheranostics.com)|ARTV (Artiva Biotherapeutics Inc.) - P/S multiplikatori|Sotuvga nisbatan narx Adlai Nortye Limited ANL|Kapitalizatsiyaning daromadga nisbati VERU (Veru Inc.)|P/S multiplikatori tempesttx.com (TPST)|Xilio Therapeutics - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati RENB (Renovaro Biosciences)|Mural Bio - P/S multiplikatori|Narx/daromad koeffitsiyenti Kairos Pharma Ltd KAPA|OKUR: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati CytoMed Therapeutics Limited|Narxning daromadga nisbati Curis Inc.|Apollomics Corp (APLM) - Narx/daromad koeffitsiyenti|Kapitalizatsiyaning daromadga nisbati THAR (Tharimmune Corp)|Narxning daromadga nisbati ADVB (advanbiomed.com)|P/S multiplikatori GNPX (Genprex, Inc.)|Narx/daromad koeffitsiyenti Calidi Biotherapeutics Inc. (CLDI)|SBFM - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati XBIO (Xenetic Biosciences)|SLRX (Salarius) - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiya va daromad nisbati PPBT|AONC (American Oncology Network Inc) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati beigene.com (BGNE)|P/S multiplikatori CKPT|P/S multiplikatori elevationoncology.com (ELEV)|Narxning daromadga nisbati iCAD ICAD|IKNA: Kapitalizatsiya va daromad nisbati|Notable Labs, Ltd. - P/S multiplikatori|morphosys.com (MOR) - Kapitalizatsiyaning daromadga nisbati|NAYA: P/S multiplikatori|Sotuvga nisbatan narx Ascentage Pharma Group International (AAPGV)
